Form 4: Hims & Hers CMO Sells $506K in Stock

Hims & Hers Health, Inc. Chief Medical Officer Patrick Harrison Carroll sold 10,021 shares of Class A Common Stock for approximately $506,060.50 under a pre-arranged trading plan.

Summary

• Patrick Harrison Carroll, Chief Medical Officer and Director of Hims & Hers Health, Inc. [HIMS], sold 10,021 shares of Class A Common Stock.
• The transaction occurred on September 17, 2025, at a price of $50.5 per share.
• The total value of the shares sold was approximately $506,060.50.
• Following this transaction, Carroll beneficially owns 169,940 shares of Class A Common Stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on May 19, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was conducted under a Rule 10b5-1 plan mitigates concerns about it being an opportunistic sale based on negative non-public information. It's a routine, pre-scheduled event.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information and is a scheduled event.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by investors as it reduces management's direct equity stake in the company.

Future Outlook

N/A

Industry Context

This is a routine insider transaction filing and does not provide specific industry context or trends. Insider trading activity is a common data point for investors to monitor within any industry.

Stakeholder Impact

• Shareholders may interpret the insider sale as a slight negative signal, although the pre-arranged 10b5-1 plan mitigates this concern. The impact is likely minimal given the routine nature of such filings.

Key Dates

Recommendation

The filing reports a planned insider sale by a key executive. While insider selling can sometimes be a bearish signal, this transaction was executed under a Rule 10b5-1 plan, which suggests it was pre-scheduled and not based on new, material non-public information. Therefore, this single transaction alone does not provide a strong enough signal to change an investment thesis, warranting a 'hold' recommendation. Investors should monitor broader company performance and market trends for more significant indicators.

Keywords

Hims & Hers Health, HIMS, Insider Sale, Patrick Harrison Carroll, CMO, Director, Stock Transaction, Form 4, 10b5-1 Plan